Why IDEXX Laboratories Stock Is Back In Focus After Q3
IDEXX Laboratories (IDXX) drew fresh attention after reporting higher third quarter revenue and earnings, then lifting its full year 2026 outlook for both sales and earnings per share.
That Q3 surprise has flipped sentiment fast. The stock has a 1 month share price return of 32.53% and a 7 day share price return of 24.10%, yet the 1 year total shareholder return is still down 3.01%. This keeps the recent rally in context against a much stronger 3 year total shareholder return of 63.32% and a more muted 5 year total shareholder return of 12.23%, as investors reassess growth prospects and risk after the upgraded 2026 outlook.
Surf 38 healthcare AI stocks that, like IDEXX Laboratories after this earnings beat and guidance lift, show strong demand drivers and fresh momentum in critical health diagnostics and data.The sharp rerating in IDEXX Laboratories after Q3 could be read as investors finally catching up to the underlying earnings power, or as sentiment swinging too far, too fast. Now the valuation has to do the explaining.
Most Popular Narrative: 0% Undervalued
The most followed valuation view pegs IDEXX Laboratories at a fair value of $701.33, almost level with the last close at $698.55. At that gap, the story is less about a bargain and more about whether the current business trajectory can support that price tag over time.
The main factor that has to go right is that IDEXX Laboratories converts underpenetrated veterinary diagnostics demand into higher bloodwork inclusion and utilization across an expanding VetLab and inVue Dx installed base, even with softer clinical visit trends.
The current numbers and guidance imply a share price that already reflects solid execution, yet still allows for potential upside if the company delivers on its long term algorithm while the stock is viewed as undervalued in this narrative’s assessment.
What is behind 30 investors see IDEXX Laboratories as 0% undervalued.
Result: Fair Value of $701.33 (ABOUT RIGHT)
Still, the IDEXX Laboratories story could be knocked off course if clinic visits stay weak for longer, or if heavier spending on new markets and AI weighs on margins.
Find out about the key risks to this IDEXX Laboratories narrative.
Another View: IDEXX Laboratories Through The P/E Lens
The fair value narrative around IDEXX Laboratories leans on a $701.33 target, but the plain P/E math tells a tougher story. At a 46.6x P/E, the stock trades well above the US Medical Equipment industry on 26.5x and peers on 33.1x, and even exceeds a fair ratio of 32.1x.
That kind of gap means little room for errors or disappointments, since any slip in execution could see investors shift the multiple closer to the fair ratio. The question is whether you believe IDEXX Laboratories can justify carrying that premium for years, or whether this is valuation risk disguised as quality.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and concern around IDEXX Laboratories feels familiar, use that tension as a prompt to move fast and test the numbers yourself. To see what those positives look like in detail, review the 2 key rewards.
Looking For More Investment Ideas Beyond IDEXX Laboratories?
If IDEXX Laboratories has sharpened your focus on quality, do not stop here. Broaden your watchlist now so you are not reacting after the next move.
- Target steadier compounding by reviewing a 5 dividend fortresses that can support income-focused portfolios when markets feel choppy.
- Hunt for potential bargains by scanning a 35 high quality undervalued stocks that blends strong fundamentals with prices that still look reasonable on key metrics.
- Prioritise resilience by filtering a 31 resilient stocks with low risk scores that keeps balance sheet strength and lower risk scores front and centre.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com